Corporations
make a difference

Read more

Treatment

The ARSACS Foundation is now
working with pharmaceutical companies
to develop a treatment for ARSACS

Read more

Several research projects
are currently funded
by the Foundation
in Canada and abroad

Read more

The Ataxia gene can be
passed through many generations
without manifesting any symptoms

Read more

We need your support
to pursue research that heals

How can you help?

Donate
`

Latest News

Spring

2015

ARSACS Research Funding for 2015-2016

The Foundation will provide again this year grants to researchers interested in ARSACS. The research grant could be as high as $100,000 for a 12 month period. If you are interested, please submit the required documents and the attached application form by May 22, 2015. See Financing Offer and ARSACS Appendix
Read more

May

10

2015

ARSACS project "PREPARE" retained for Phase 2 of the E-Rare-3 competition

As part of the international competition E-Rare-3 European Research Projects on Rare Diseases, the ARSACS project entitled "PREPARE" led by Dr. Matthis Synofzik (Germany) was selected for phase 2 of the competition.

Read more

May

06

2015

Anti-Sacsin Antibody now available

Anti-Sacsin Antibody now available through Millipore(product # ABN1019). For more information, click Millipore.

April

23

2015

Interdisciplinary Conference on neuromuscular diseases and amyotrophic lateral sclerosis

An interdisciplinary conference on neuromuscular diseases and amyotrophic lateral sclerosis was held on April 16 & 17. This event was attended by professionals who specialize in the care of patients with neuromuscular disease and ALS. ARSACS was the topic of discussion at several occasions.

Read more

April

15

2015

International collaboration to accelerate scientific discovery

An international working group held a meeting in the UK on March 25, 2015 to discuss clinical measures that could be used to establish the efficacy of drugs in the treatment of Ataxia of Charlevoix-Saguenay.

Read more

March

30

2015

Dr. Matthis Synofzik's project update

Update on Dr. Synofzik's research "A randomised delayed entry trial of intensive home-based speech therapy in ARSACS" project funded by the Foundation.

Read more

March

11

2015

Research of the role of the Sacsin on human cells

Dr. Jonathon Burman, Ph.D.researcher(Research Fellow) will study the role of the Sacsin on human cells. Dr. Burman is part of Dr. Richard Youle's research lab at the National Institutes of Health (NIH) Maryland, USA. See Dr. Burman's project abstract.

Fev

27

2015

Discussions with an american cie

Preliminary discussions are underway with an american pharmaceutical cie to test a drug for ARSACS (preclinical trial). More information to follow.


Who We Are


What We Do

Funding
Funding
process
Team
Research
Research
process
Discovery
Trials
Trials

The Ataxia Charlevoix-Saguenay Foundation is a charitable organisation supported entirely by private donations. Different events are organised during the year by families, friends and community groups to raise funds to support research on ARSACS.


Since its creation, the Foundation has been successful in assembling a great team at all levels of the organisation (board, advisors, researchers, contributors and partners). The researchers are well respected in their field and have an international reputation for excellence.


The main research objective of the Ataxia Charlevoix-Saguenay Foundation is to develop a treatment for ARSACS. Several research projects on ARSACS are currently funded by the Foundation in Canada and abroad. Over 98% of the funds raised are allocated to research.


The main research objective of the Ataxia Charlevoix-Saguenay Foundation is to develop a treatment for ARSACS.


The first therapeutic tests on transgenic ARSACS mice conducted in the Spring 2013 were very positive. For a short study, the tests demonstrated some beneficial effect on the physical performance of the mice. Discussions are underway to determine the next step.